INVOKAMET XR Drug Patent Profile

When do Invokamet Xr patents expire, and what generic alternatives are available?

Invokamet Xr is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokamet Xr

Invokamet Xr was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 14, 2028. This may change due to patent challenges or generic licensing.

There have been thirty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INVOKAMET XR

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for INVOKAMET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKAMET XR
DailyMed Link:	INVOKAMET XR at DailyMed

See drug prices for INVOKAMET XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVOKAMET XR

NDA:

205879

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INVOKAMET XR

Drug Class	Biguanide Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INVOKAMET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKAMET XR	Extended-release Tablets	canagliflozin; metformin hydrochloride	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	205879	1	2018-11-21

US Patents and Regulatory Information for INVOKAMET XR

INVOKAMET XR is protected by three US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-004	Sep 20, 2016		RX	Yes	Yes					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No

Expired US Patents for INVOKAMET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-004	Sep 20, 2016

International Patents for INVOKAMET XR

See the table below for patents covering INVOKAMET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	536863
Australia	2002337974
Canada	2409999	MELANGES DE POLYMERES OPTIQUES POUR DES COMPRIMES POUVANT ETRE RETENUS DANS L'ESTOMAC (OPTICAL POLYMER MIXTURES FOR GASTRIC RETENTIVE TABLETS)
European Patent Office	1446106	MÉLANGES DE POLYMÈRES OPTIMAUX POUR COMPRIMÉS A RÉTENTION GASTRIQUE (OPTIMAL POLYMER MIXTURES FOR GASTRIC RETENTIVE TABLETS)
European Patent Office	2260832
Japan	2005532985

Supplementary Protection Certificates for INVOKAMET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	2014/029	Ireland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1651658	PA2014008	Lithuania		PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
1651658	CA 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
1651658	C300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
1651658	92426	Luxembourg		PRODUCT NAME: CANAGLIFLOZINE
1651658	C20140011 00102	Estonia		PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013

INVOKAMET XR Market Dynamics and Financial Trajectory (2024–2029): Pricing, Uptake, Competitive Threat, and Loss-of-Exclusivity Risks

Last updated: July 23, 2026

Executive summary: INVOKAMET XR (canagliflozin/metformin HCl extended-release) sits in the crowded SGLT2 inhibitor plus metformin landscape and faces intensifying share pressure from (1) SGLT2 inhibitor monotherapy and fixed-dose combinations with once-daily dosing convenience, (2) GLP-1 and dual incretin uptake in type 2 diabetes, and (3) payer-driven step edits that favor preferred brands and lower net price. Its financial trajectory is shaped by the timing of patent and regulatory exclusivity expirations for the fixed-dose combination, the pace of generic metformin and component erosion, and whether canagliflozin-related exclusivity and combination-specific patents extend the competitive moat.

Because INVOKAMET XR’s exact current net sales, segment shares, and remaining exclusivity dates are not provided in the prompt, this analysis cannot produce complete, accuracy-guaranteed financial figures or a definitive exclusivity calendar without external record-level inputs.

---

What is INVOKAMET XR and how does it fit into the SGLT2 plus metformin type 2 diabetes market?

Featured snippet answer: INVOKAMET XR combines canagliflozin (SGLT2 inhibitor) with metformin extended-release in a single once-daily product targeting type 2 diabetes patients who need both glycemic control and SGLT2-class cardiorenal benefits.

Core positioning

• Mechanism: SGLT2 inhibition plus metformin lowers glucose via renal glucose excretion and hepatic gluconeogenesis modulation.
• Patient segment: People with type 2 diabetes inadequately controlled on metformin alone or who benefit from early SGLT2-class outcomes.
• Formulation promise: Extended-release metformin supports once-daily combination dosing, reducing pill burden versus taking two separate products.

Market adjacency

• SGLT2 inhibitor monotherapy (preferred by some formularies for easier titration and stronger payer preference dynamics).
• Other SGLT2 fixed-dose combinations with metformin or other agents, where dosing simplicity and negotiated rebates can shift share quickly.
• GLP-1 receptor agonists and dual agonists (increasingly displacing SGLT2 initiation for many payers due to weight and A1c targets).

---

How do pricing, rebates, and payer design affect INVOKAMET XR net revenue trajectory?

Featured snippet answer: Net revenue for fixed-dose combinations depends less on list price and more on formulary placement, rebate intensity, and step therapy that favors preferred SGLT2 brands and alternative combination pathways.

Payer mechanics that move the needle

1. Formulary tiers and step edits

   • Plans often steer to SGLT2 monotherapy first or to a preferred combination if it is cheaper on net.
   • Step edits and prior authorizations reduce market expansion even when clinical uptake is steady.

2. Net price compression from brand-to-brand competition

   • When multiple SGLT2-based fixed-dose options exist, negotiated rebates rise to retain placement.
   • Even without generic entry, net prices can fall due to competitive bidding cycles.

3. Component reimbursement dynamics

   • Metformin is widely generic, so the economic value is concentrated in canagliflozin access.
   • Fixed-dose combinations can still suffer if payers prefer separate dispensing structures or cheaper alternatives.

Implication for INVOKAMET XR

• INVOKAMET XR’s financial trajectory is typically characterized by:
  • Initial pull from clinicians preferring combination therapy
  • Gradual share erosion when payers lock in preferred SGLT2 brands or favored fixed-dose rivals
  • Ongoing net price pressure rather than “cliff” revenue loss unless combination-specific exclusivity ends

---

What competitive threats most affect INVOKAMET XR market share (SGLT2, GLP-1, and combination strategy)?

Featured snippet answer: The highest share risk comes from SGLT2 class substitutes with stronger payer preference and from GLP-1 and dual agonists that increasingly dominate late-line and weight-targeted prescribing.

SGLT2 competitive set dynamics

• Class competition: Multiple SGLT2 inhibitors compete on outcomes evidence, dosing frequency, and payer contracts.
• Fixed-dose convenience: Competitors with equal or simpler dosing can displace INVOKAMET XR if net price is lower.
• Indication expansion: Broader label utility can support persistence, but only if payer coverage follows.

GLP-1 / dual agonist displacement

• Therapeutic shift: Many clinicians now start with incretin-based therapies when weight loss is a priority.
• Payer strategy: Formularies increasingly favor one “preferred” obesity and diabetes portfolio to minimize total covered costs.

Net effect

• Even if INVOKAMET XR maintains prescriptions among those needing SGLT2 benefits, its growth typically slows while share migrates toward the most favored plan offerings.

---

When does INVOKAMET XR lose exclusivity, and how does that change the financial model?

Featured snippet answer: Loss of exclusivity is driven by combination-specific patent expiry and FDA exclusivity milestones, which determine whether generic fixed-dose copies or AB-rated canagliflozin/metformin combinations can enter without infringement exposure.

Exclusivity channels that matter

• Orange Book-listed patents (drug product, composition, method-of-use, and manufacturing/process)
• Patent term and patent expiration schedule
• Regulatory exclusivity (where applicable) tied to New Drug Application milestones
• Paragraph IV litigation risk that can delay launch if patents are challenged and injunctions/settlements occur

Financial modeling impact

• Pre-expiry period: Volume growth is constrained mainly by payer preference, not patent risk.
• Post-expiry period: Revenue typically faces stepwise declines if generics enter and pricing falls to generic parity rates.
• Litigation outcomes: Settlements can push generic launch timing and create “evergreen” delays if mechanisms exist.

This section cannot be completed with exact dates and case numbers from record-level sources because the prompt does not include INVOKAMET XR’s FDA Orange Book patent list, filing history, or litigation docket.

---

What patent estate features would determine generic entry risk for INVOKAMET XR?

Featured snippet answer: Generic entry risk depends on whether the fixed-dose combination’s protected elements include canagliflozin/metformin XR formulation aspects, method-of-use claims, or manufacturing/process constraints.

Key patent estate categories

• Composition patents for fixed-dose combinations and specific XR formulation
• Formulation/manufacturing patents tied to extended-release technology
• Method-of-use patents for dosing regimens and clinical benefit claims
• Device or packaging claims (less common for small molecules but can appear)

How it maps to entry scenarios

• If only canagliflozin is protected: generics can sometimes launch a combination if they can avoid infringed claims on the remaining elements.
• If combination-specific XR formulation is protected: generic launches are more likely delayed or forced into non-infringing workaround products.
• If method-of-use is protected: generic product may launch but labeling restrictions can limit uptake.

Accurate counts, jurisdictions, assignees, and expiration dates require Orange Book and patent family records not included in the prompt.

---

What generic launch scenarios exist for INVOKAMET XR, and what timing would drive revenue decline?

Featured snippet answer: The most revenue-impacting scenario is the first authorized or court-cleared generic fixed-dose XR combination launch, typically followed by rapid price competition and formulary switches.

Scenario framework

1. At-patent-expiry “at risk” entry
   • If a generic can clear the patent thicket or wins litigation, launch can happen shortly after relevant expirations.
2. Paragraph IV settlement delay
   • Settlement can extend commercial exclusivity indirectly by delaying generic entry dates.
3. Label carve-outs
   • If method-of-use is under dispute, launch can occur with restricted claims, slowing uptake and softening revenue erosion.

What to watch operationally

• FDA approvals and product labeling for AB-rated generics
• Orange Book changes (patent listings removed or added)
• Litigation orders affecting launch timing

This prompt does not provide any Orange Book update history or litigation docket information, so a time-anchored scenario schedule cannot be produced accurately.

---

What is the Orange Book status of INVOKAMET XR, and how many patents cover it?

Featured snippet answer: Orange Book status depends on drug product listings and patent families for canagliflozin/metformin XR; counts vary by product strength and dosage form.

This section cannot be filled with:

• the number of listed patents,
• their expiration dates,
• and whether they are composition, method-of-use, or formulation/manufacturing, because no Orange Book identifier, NDC list, or patent listing data is provided in the prompt.

---

How do manufacturing and supply constraints influence INVOKAMET XR revenue stability?

Featured snippet answer: For extended-release fixed-dose products, supply stability can affect revenue disproportionately during formulary transitions and payer switching because prescribers often avoid backorders and inconsistent availability.

Operational factors

• Scale-up and blending uniformity for extended-release metformin
• Canagliflozin API supply stability and lot release controls
• Line clearance and changeover during strength transitions
• Quality events that can cause temporary distribution pauses and lost channel momentum

This analysis cannot quantify supply interruptions or quality events without record-level evidence.

---

How does INVOKAMET XR compare with key rivals on dosing convenience and payer fit?

Featured snippet answer: INVOKAMET XR’s advantage is once-daily fixed dosing; its disadvantage is that payer preference can shift to competing SGLT2 fixed-dose products with stronger contracting economics.

Comparison axes

• Dosing frequency: once-daily versus titration complexity
• Formulary positioning: preferred vs non-preferred tiers
• Net pricing: rebate structure versus competitors
• Patient adherence: reduced pill burden vs alternative regimens
• Clinical breadth: label fit for cardiovascular and renal outcomes depending on evolving guideline adoption

Without competitor-specific net price and formulary tier data, a ranked comparison cannot be provided.

---

What FDA and regulatory developments drive market dynamics for INVOKAMET XR?

Featured snippet answer: Regulatory dynamics primarily affect INVOKAMET XR through labeling, REMS (if any), safety communications, and any supplemental approvals affecting coverage decisions.

Potential regulatory drivers

• New label expansions can support formulary re-evaluation.
• Safety updates can alter prior authorization criteria or clinician adoption.
• Generic approvals and AB ratings change substitution dynamics.

Record-level FDA history is not supplied in the prompt, so specific FDA events cannot be listed.

---

Commercial trajectory: what revenue pattern typically appears for an SGLT2 fixed-dose XR brand?

Featured snippet answer: Fixed-dose SGLT2 combinations typically show growth early in lifecycle, then plateau as class competition increases, followed by revenue decline tied to net price compression and eventual generic entry of combination formulations.

Revenue pattern (high-level, non-quantitative)

• Early-to-mid phase: volume gains driven by combination prescribing and conversion from metformin alone.
• Mid phase: payer pressure increases; net price falls; market growth slows.
• Late phase: share shifts to the most preferred SGLT2 product; GLP-1 displacement becomes visible in later-line prescribing.
• Exclusivity phase change: revenue drops quickly once fixed-dose generics enter unless settlement delays or labeling carve-outs soften substitution.

Quantitative projections require INVOKAMET XR’s actual sales baseline, channel mix, rebate rates, and remaining exclusivity dates, which are not included.

---

Key risks and upside levers for INVOKAMET XR (2024–2029)

Key downside risks

• Formulary loss to preferred SGLT2 brands or competing fixed-dose combinations
• Increased GLP-1 and dual agonist prescribing displacing SGLT2 combinations in many patient journeys
• Generic entry if combination-specific patents and XR formulation protections expire and are cleared

Potential upside levers

• Outcome-driven guideline adherence expanding early SGLT2 use in eligible populations
• Payer contract renegotiation that restores preferred status and improves net price
• Litigation outcomes that delay generic entry and sustain price leadership longer than baseline modeling

---

Key Takeaways

• INVOKAMET XR competes in a high-pressure SGLT2 plus metformin segment where payer contracting and net price drive outcomes more than gross list price.
• Market share growth is constrained by formulary step edits and increasingly by incretin-based displacement.
• The most material financial inflection is the timing of combination-specific exclusivity and patent clearance that enables fixed-dose XR generic substitution.
• A full, accuracy-guaranteed financial trajectory requires Orange Book patent lists, exclusivity milestones, and any Paragraph IV litigation or settlement dates tied to INVOKAMET XR, none of which were provided in the prompt.

---

FAQs

1. How does fixed-dose SGLT2/metformin pricing usually change after generic metformin introduction?
2. Do method-of-use labeling restrictions meaningfully slow generic uptake for SGLT2 fixed-dose combinations?
3. What payer tactics most quickly reduce the share of non-preferred diabetes brands?
4. How do GLP-1 and dual agonists alter the sequencing from SGLT2 combinations to incretin therapy?
5. What events in Orange Book maintenance most predict the earliest generic launch windows?

---

References

1. No sources were cited because no record-level FDA Orange Book, patent, litigation, or financial data for INVOKAMET XR was provided in the prompt.